154 related articles for article (PubMed ID: 11426615)
21. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis.
Tsiara SN; Chaidos A; Bourantas LK; Kapsali HD; Bourantas KL
Acta Haematol; 2007; 117(3):156-61. PubMed ID: 17159338
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics.
Cotes PM; Pippard MJ; Reid CD; Winearls CG; Oliver DO; Royston JP
Q J Med; 1989 Feb; 70(262):113-37. PubMed ID: 2594953
[TBL] [Abstract][Full Text] [Related]
23. Erythropoietin and the anaemia of chronic disease.
Krantz SB
Nephrol Dial Transplant; 1995; 10 Suppl 2():10-7. PubMed ID: 7644100
[TBL] [Abstract][Full Text] [Related]
24. [The correction of anemia with a high requirement for transfusion in patients on maintenance hemodialysis by conventional and reduced doses of recombinant human erythropoietin].
Sivak L; Scuteri RM; Cavalli NH; Gotlieb D; López Blanco OA
Medicina (B Aires); 1992; 52(6):516-22. PubMed ID: 1340900
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
Phair JP; Abels RI; McNeill MV; Sullivan DJ
Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
[TBL] [Abstract][Full Text] [Related]
26. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
[TBL] [Abstract][Full Text] [Related]
27. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous.
Hörl WH
Acta Haematol; 1992; 87 Suppl 1():16-9. PubMed ID: 1574961
[TBL] [Abstract][Full Text] [Related]
28. The effect of subcutaneous r-HuEPO in cancer patients receiving chemotherapy with anemia: a preliminary report.
Chiou TJ; Chim YS; Wei CH; Hsieh RK; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 1997 Nov; 60(5):229-35. PubMed ID: 9509677
[TBL] [Abstract][Full Text] [Related]
29. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
Frenken LA; Verberckmoes R; Michielsen P; Koene RA
Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
[TBL] [Abstract][Full Text] [Related]
31. Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritis.
Nordström D; Lindroth Y; Marsal L; Hafström I; Henrich C; Rantapää-Dahlqvist S; Engström-Laurent A; Fyhrquist F; Friman C
Rheumatol Int; 1997; 17(2):67-73. PubMed ID: 9266623
[TBL] [Abstract][Full Text] [Related]
32. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of tumor necrosis factor-alpha and erythropoietin serum levels in B-cell chronic lymphocytic leukemia patients with anemia.
Capalbo S; Battista C; Delia M; Ciancio A; De Santis G; Dargenio M; Diomede D; Liso V
Acta Haematol; 2002; 108(2):84-9. PubMed ID: 12187026
[TBL] [Abstract][Full Text] [Related]
34. Subcutaneous r-HuEPO therapy in CAPD patients: dose determination and clinical experience.
Janicka L; Ksiazek A; Baranowicz I; Bednarek-Skublewska A; Mierzicki P; Ksiazek P
Int Urol Nephrol; 1998; 30(1):91-7. PubMed ID: 9569119
[TBL] [Abstract][Full Text] [Related]
35. [Clinical Features and Outcomes of the Patients with B-Cell Chronic Lymphoproliferative Disease in the New Drug Era].
Xu CB; Hu M; Shen JZ; Xu HQ; Zheng RJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):722-729. PubMed ID: 37356932
[TBL] [Abstract][Full Text] [Related]
36. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.
Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P
Eur J Cancer; 2004 Oct; 40(15):2201-16. PubMed ID: 15454245
[TBL] [Abstract][Full Text] [Related]
37. Adhesion molecules in B-chronic lymphoproliferative disorders.
Angelopoulou MK; Kontopidou FN; Pangalis GA
Semin Hematol; 1999 Apr; 36(2):178-97. PubMed ID: 10319387
[TBL] [Abstract][Full Text] [Related]
38. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients.
Goicoechea M; Vazquez MI; Ruiz MA; Gomez-Campdera F; Perez-García R; Valderrábano F
Nephron; 1998; 78(1):23-7. PubMed ID: 9453399
[TBL] [Abstract][Full Text] [Related]
39. [Recombinant erythropoietin (r-HuEPO) in the treatment of anemia in multiple myeloma].
Spicka I; Haber J; Petruzelka L; Kolesková E; Sálková J; Straub J; Zounar R; Klener P
Cas Lek Cesk; 1996 Jul; 135(14):450-3. PubMed ID: 8925545
[TBL] [Abstract][Full Text] [Related]
40. The future of r-HuEPO.
Eschbach JW
Nephrol Dial Transplant; 1995; 10 Suppl 2():96-109. PubMed ID: 7644114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
